Cargando…

OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind

Background: Dulaglutide (DU) was superior to placebo (PL) in reducing the incidence of Major Adverse Cardiovascular Events in the Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND Study) broad patient population. The safety of DU treatment is also of interest to health car...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konig, Manige, Gerstein, Hertzel C, Lakshmanan, Mark C, Xavier, Denis, Atisso, Charles, Allen, Sheryl, Cushman, William C, Leiter, Lawrence A, Raubenheimer, Peter J, Franek, Edward M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Diabetes Mellitus and Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207332/ http://dx.doi.org/10.1210/jendso/bvaa046.071

Ejemplares similares

Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
por: Riddle, Matthew C, et al.
Publicado: (2021)

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
por: Konig, Manige, et al.
Publicado: (2021)

Necrotizing Pancreatitis Secondary to Dulaglutide Use
por: Bhat, Salman Zahoor, et al.
Publicado: (2021)

FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US
por: Hoog, Meredith, et al.
Publicado: (2023)

Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide
por: Ghosh, Aneesh
Publicado: (2021)

Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist
por: Quadri, Hamza, et al.
Publicado: (2021)

MON-636 The Relationship Between Glucose Control & Cognitive Function in People with Diabetes After a Lacunar Stroke
por: Cukierman-Yaffe, Tali, et al.
Publicado: (2020)

MON-681 Dulaglutide Commonly Known as Trulicity; An Anti-Diabetic Medication Causing Small Bowel Obstruction
por: Gandhi, Ankita, et al.
Publicado: (2020)

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
por: Frias, Juan Pablo, et al.
Publicado: (2021)

HbA(1c) Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
por: Kwan, Anita Y.M., et al.
Publicado: (2022)

Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

OR26-08 Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel ARM Study (Award-11)
por: Frias, Juan Pablo, et al.
Publicado: (2020)

Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
por: Franek, Edward, et al.
Publicado: (2022)

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
por: Dagenais, Gilles R., et al.
Publicado: (2020)

OR08-06 Increased Carotid Intima Media Thickness in Pediatric Type 1 Diabetes Is Associated with Disease Duration
por: Cohen, Michal, et al.
Publicado: (2020)

OR26-06 Fecal Microbiota Transplantation Trial for the Improvement of Metabolism (FMT-TRIM): A Randomized Double-Blind Placebo-Controlled Pilot Trial
por: Yu, Elaine Wei-Yin, et al.
Publicado: (2020)

OR14-06 Inhibition of Protein Kinase C-beta2 Phosphorylation Restores Nuclear Factor-Kappa B Activation and Improves Peripheral Arterial Disease in Diabetes
por: Alleboina, Satyanarayana, et al.
Publicado: (2020)

OR30-04 Autonomous Drone Delivery of Insulin
por: O’Keeffe, Derek Timothy, et al.
Publicado: (2020)

FRI646 Dulaglutide-induced Acute Liver Injury - A Case Report
por: Shahid, Maham, et al.
Publicado: (2023)

Clinical Utility of 30-Min Postload Plasma Glucose in Paediatric Obesity
por: Poon, Sarah Wing-yiu, et al.
Publicado: (2021)

SAT-628 Risk Factors Associated with 30-Day and 90-Day Readmission in Persons with Diabetic Foot Ulcers
por: Dawkins, Makeda, et al.
Publicado: (2020)

OR30-03 Racial Differences in Technology Use Among Type 1 Diabetes in a Safety-Net Hospital
por: Wirunsawanya, Kamonkiat, et al.
Publicado: (2020)

PSUN241 A Case of Dulaglutide-Induced Acute Pancreatitis in a Diabetic Patient – A Case Report
por: Abdelmasih, Randa, et al.
Publicado: (2022)

Rates and Predictors of 30-Day Readmission in Adults with Type 1 Diabetes Hospitalized for Diabetic Ketoacidosis in the US: A Nationwide Study
por: Shaka, Hafeez, et al.
Publicado: (2021)

SUN-615 Does Patient Location (Urban or Rural) Influence Risk Factors and Incidence Rate for 30-Day Readmission for Diabetic Ketoacidosis?
por: Varghese, Ron Thomas, et al.
Publicado: (2020)

OR30-01 Real-World Minimed™ 670G System Use and Glycemic Outcomes of Pediatric and Adult Individuals Living with Type 1 Diabetes (T1D) in the United States
por: Vigersky, Robert Alan, et al.
Publicado: (2020)

LBSUN319 Characteristics And Treatment Patterns Of Hispanic/latino Patients Initiating First Injectable Glp-1ra Or Basal Insulin
por: Hoog, Meredith, et al.
Publicado: (2022)

PSUN270 Magnified Risk of Pancreatitis by GLP-1: A Case of Necrotizing Pancreatitis in a Patient on Dulaglutide with Baseline Elevated Triglycerides
por: Yau, Alice, et al.
Publicado: (2022)

OR30-02 Efficacy and Safety Comparison Between U100 Regular Human Insulin and U100 Rapid Acting Insulin When Delivered by a 24 Hour Wearable Insulin Delivery Device in Type 2 Diabetes
por: Mora, Pablo, et al.
Publicado: (2020)

OR18-06 Metabolomic And Genetic Architecture Of Gestational Diabetes Subtypes
por: Lee, Kristen, et al.
Publicado: (2023)

MON-660 Hypoglycemia Following OGTT Is More Frequent and Pronounced in CF Compared with Controls
por: Harris, Clea D, et al.
Publicado: (2020)

OR30-07 Mixed Meal Tolerance Test (MMTT) Results from Revita-2, the First Randomized, Sham-Controlled, Double-Blind, Prospective, Multicenter Study of Duodenal Mucosal Resurfacing (DMR) Safety and Efficacy in Patients with Sub-Optimally Controlled Type 2 Diabetes (T2D)
por: Hopkins, David, et al.
Publicado: (2020)

General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial
por: Franek, Edward, et al.
Publicado: (2023)

MON-184 Hypoglycemia During Mixed Meal Tolerance Testing and Early Glucose Dysregulation in Cystic Fibrosis
por: Kilberg, Marissa, et al.
Publicado: (2019)

Review on the Screening of Urine Glucose in School Children and Adolescents With Obesity for Early Diagnosis of Type 2 Diabetes Mellitus in Hong Kong
por: Pang, Gloria S W, et al.
Publicado: (2021)

SUN-685 Approach to a Potential Liver Transplant Candidate with Insulin Antibody-Mediated Severe Insulin Resistance
por: Brooks, Danielle C, et al.
Publicado: (2020)

Endocrinology in the Time of Coronavirus: A Virtual Endocrinology Elective for Medical Students
por: Moxley, Meaghan C, et al.
Publicado: (2021)

Prevalence and Predictors of Hepatic Steatosis Among Adult Population With Prediabetes: Data From NHANES 2017–2018
por: Shaheen, Magda, et al.
Publicado: (2021)

Scientific and Regulatory Considerations for the Approval of the First Generic Glucagon
por: Pang, Eric, et al.
Publicado: (2021)

SUN-640 Sex-Specific Difference in REG3G Expression Directs the Maintenance of Islet Function in Offspring of Obese Mice
por: Casasnovas, Jose, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g4tc6i5ch8reuc2no37ug1pomf